Immunexpress Inc.

'Tis the season, and influenza, like any infectious disease, can be a cause of #sepsis. There are a number of common signs and symptoms of sepsis, and you can learn more about them here: https://bit.ly/3VXztnH #SepsisAwareness

If you haven’t yet listened to our CEO Rollie Carlson in conversation with host Meg Sinclair about the importance of accurate #sepsis detection and our SeptiCyte® RAPID technology on the From Lab to Launch podcast, you can find the episode here: https://apple.co/3TsYmsn

Stopping sepsis is a team effort! Immunexpress is committed to providing physicians with the tools they need to save lives—quickly and effectively. #SepsisAwareness #EmpoweringPhysicians #SavingLives

In the fight against sepsis, every second counts. With accurate, rapid diagnostics, physicians can make timely decisions that save lives. Sepsis is a leading cause of death worldwide, but early detection can make all the difference. By providing healthcare professionals with the tools they need, Immunexpress is not just diagnosing sepsis; we’re helping save lives

#Sepsis can strike at any age, but adults over the age of 65 are most at risk, being 13 times more likely to be hospitalized with sepsis. Learn more here: https://bit.ly/4g12mcG

Hot off the press! A recent peer-reviewed study published in Infection found that SeptiCyte® RAPID was able to distinguish between #sepsis and sterile inflammation among patients recovering from abdominal surgery. Sepsis is a major concern in the context of post-surgical complications. These findings emphasize the promise and potential of our point-of-care molecular host response assay in helping physicians diagnose #sepsis among patients recovering from surgery. Read the full announcement here: https://prn.to/4eXR5sq See the full study here: https://bit.ly/3CYOuRO

From all of us at Immunexpress, we wish everyone a safe and happy Thanksgiving holiday!

Dr. Alyse Wheelock of The Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO) recently presented data on the use of SeptiCyte® RAPID in #sepsis longitudinal monitoring in malaria, and its utility in assessing the severity of parasitic infection and patient response to treatment.

Last week, Immunexpress Inc. presented at WiSE Pathology Laboratory and Peter MacCallum Cancer Centre to an audience of scientists and clinicians. Immunexpress’s Jane (Markley) Papadaki (VP of Commercial Operations) and Richard Brandon (Chief Scientific Officer) discussed: • SeptiCyte RAPID’s applicability for early sepsis identification. • Challenges of diagnosing sepsis in immunocompromised or cancer patients. Thank you to Jane, Richard, and all attendees for their commitment to improving patient outcomes. Learn more about SeptiCyte RAPID → https://lnkd.in/gkZneHyz #abacusdx #immunexpress #sepsis #septicyte

Dr. Alyse Wheelock of the Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO) recently presented at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting on the usefulness of SeptiCyte® RAPID in #sepsis longitudinal monitoring. An elevated SeptiScore® at patient admission decreased as symptoms diminished over 72 hours and sepsis resolved with treatment.